会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明公开
    • 도메인 치환법에 의한 글리코실트랜스퍼라아제하이브리드의 제조방법
    • 使用域切换进行糖基转移酶杂交的制备方法
    • KR1020090038731A
    • 2009-04-21
    • KR1020070104183
    • 2007-10-16
    • 주식회사 진켐
    • 우진석송재경김병기이희찬류광경김대희강선엽박성희양지영서원민길태건심상희
    • C12N9/10C12N9/00
    • A method for preparing glycosyltransferase hybrid through domain substitution is provided to generate glycosyltransferase hybrid having C-terminal domain derived from the first glycosyltransferase and N-terminal domain derived from the second glycosyltransferase. Glycosyltransferase hybrid comprises C-terminal domain derived from the first glycosyltransferase and N-terminal domain derived from the second glycosyltransferase. The C-terminal domain derived from the first glycosyltransferase and N-terminal domain derived from the second glycosyltransferase are linked with each other by linker loop. The first glycosyltransferase and the second glycosyltransferase are respectively selected from the group consisting of GtFA, GtFB, GtFC, GtFD, GtFE, KanF, BtrM, GtmG, NemD, RbmD and TbmD. A method for preparing the glycosyltransferase hybrid consists of the following steps of: preparing a recombinant vector having a gene coding glycosyltransferase hybrid; transforming a microorganism with the recombinant vector; and cultivating the transformed microorganism to obtain the glycosyltransferase hybrid.
    • 提供通过领域取代制备糖基转移酶杂交体的方法,以产生具有衍生自第一糖基转移酶的C-末端结构域和衍生自第二糖基转移酶的N末端结构域的糖基转移酶杂交体。 糖基转移酶杂合物包含衍生自第一糖基转移酶的C-末端结构域和衍生自第二糖基转移酶的N-末端结构域。 衍生自第一糖基转移酶的C末端结构域和衍生自第二糖基转移酶的N-末端结构域通过接头环相互连接。 第一糖基转移酶和第二糖基转移酶分别选自GtFA,GtFB,GtFC,GtFD,GtFE,KanF,BtrM,GtmG,NemD,RbmD和TbmD。 制备糖基转移酶杂交体的方法包括以下步骤:制备具有编码糖基转移酶杂交基因的重组载体; 用重组载体转化微生物; 并培养转化的微生物以获得糖基转移酶杂交体。
    • 6. 发明公开
    • 신규 N―아세틸글루코사민―2―에피머라아제 및 이를이용한 CMP―N―아세틸뉴라민산의 제조방법
    • 新型N-乙酰谷氨酰胺-2-EPIMERASE和使用该产物制备CMP-神经酰胺酸的方法
    • KR1020080055588A
    • 2008-06-19
    • KR1020070056919
    • 2007-06-11
    • 주식회사 진켐
    • 우진석송재경김병기강선엽김대희장경순양지영서원민길태건심상희허인강
    • C12N9/00C12N9/88
    • C12N9/90C12P17/16
    • A novel N-acetylglucosamine-2-epimerase is provided to produce a large quantity of CMP(cytidine monophosphate)-N-acetylneuraminic acid economically through one reaction by using inexpensive substrates of cytidine monophosphate and N-acetyl-D-glucosamine. A novel N-acetylglucosamine-2-epimerase has the amino acid sequence of SEQ ID NO:2. A gene encoding the N-acetylglucosamine-2-epimerase has the nucleotide sequence of SEQ ID NO:1. The N-acetyl-D-mannosamine is produced by reacting the reaction mixture containing N-acetyl-D-glucosamine in the presence of N-acetylglucosamine-2-epimerase. The neuraminic acid is produced by reacting the reaction mixture containing N-acetyl-D-mannosamine in the presence of N-acetylneuraminic acid aldolase. The CMP-N-acetylneuraminic acid is produced by reacting a reaction mixture containing cytidine 5' monophosphate(CMP), nucleotide tri-phosphate(NTP) or ATP, acetyl phosphate(acetyl Pi), N-acetyl-D-glucosamine and pyruvic acid in the presence of N-acetylglucosamine-2-epimerase(GlcNAc 2-epimerase), N-acetylneuraminic acid aldolase(NeuNAc aldolase), acetate kinase and CMP-N- acetylneuraminic acid synthetase.
    • 提供新的N-乙酰葡糖胺-2-差向异构酶,通过使用胞苷单磷酸和N-乙酰基-D-葡糖胺的廉价底物,通过一次反应经济地产生大量的CMP(胞苷一磷酸)-N-乙酰神经氨酸。 新型N-乙酰葡糖胺-2-差向异构酶具有SEQ ID NO:2的氨基酸序列。 编码N-乙酰葡糖胺-2-差向异构酶的基因具有SEQ ID NO:1的核苷酸序列。 通过在N-乙酰基葡糖胺-2-差向异构酶的存在下使含有N-乙酰基-D-葡糖胺的反应混合物反应来制备N-乙酰基-D-甘露糖胺。 通过在N-乙酰神经氨酸醛缩酶存在下使含有N-乙酰基-D-甘露糖胺的反应混合物反应来制备神经氨酸。 通过使含有胞苷5'-单磷酸(CMP),三磷酸核苷酸(NTP)或ATP,乙酰基磷酸酯(乙酰基Pi),N-乙酰基-D-葡糖胺和丙酮酸的反应混合物反应制备CMP-N-乙酰神经氨酸 在N-乙酰氨基葡萄糖-2-差向异构酶(GlcNAc 2-差向异构酶),N-乙酰神经氨酸醛缩酶(NeuNAc醛缩酶),乙酸激酶和CMP-N-乙酰神经氨酸合成酶的存在下。
    • 8. 发明公开
    • 반코마이신 유도체 및 그의 제조방법
    • VANCOMYCIN衍生物及其生产方法
    • KR1020100009291A
    • 2010-01-27
    • KR1020080070125
    • 2008-07-18
    • 주식회사 진켐
    • 우진석송재경김대희강선엽양지영서원민심상희오태진
    • C12P19/44C12P19/60
    • C12P19/445C07H17/00C12Y204/00
    • PURPOSE: A vancomycin derivative in which monosaccharide is bound is provided to ensure tolerance to vancomycin and has high physiological activity. CONSTITUTION: A vancomycin derivative has vancomycin of chemical formula 1 or D-glucose of pseudo-vancomycin of chemical formula 2 which one or more monosaccharide is bound. The monosaccharide is glucose, fructose, mannose, galactose, ribose, or amino saccharide. The monosaccharide is galactose, the galactose is bound with sialic acid. The amino acid saccharide is sialic acid. A method for preparing the vancomyxin derivative comprises: a step of performing glycosyl transition of vancomycin or pseudo vancomycin aglycon to obtain one or more monosaccharide-bound vancomycin derivative complex; and a step of purifying the monosaccharide-bound vancomycin derivative complex through chromatography.
    • 目的:提供单糖结合的万古霉素衍生物,以确保对万古霉素的耐受性,并具有高生理活性。 构成:万古霉素衍生物具有化学式1的万古霉素或一种或多种单糖结合的化学式2的假万古霉素的D-葡萄糖。 单糖是葡萄糖,果糖,甘露糖,半乳糖,核糖或氨基糖。 单糖是半乳糖,半乳糖与唾液酸结合。 氨基酸糖是唾液酸。 制备万康霉素衍生物的方法包括:进行万古霉素或假万古霉素糖苷配基的糖基转变以获得一种或多种与单糖结合的万古霉素衍生物复合物的步骤; 以及通过色谱法纯化单糖结合的万古霉素衍生物复合物的步骤。
    • 9. 发明公开
    • 신규 2,3―시알릭 전이효소 및 이를 이용한 말단에갈락토오스를 포함하는 물질의 제조방법
    • 新型2,3-硅缩水甘油酯及其终产物中具有糖膏的化合物的方法
    • KR1020080092662A
    • 2008-10-16
    • KR1020070036276
    • 2007-04-13
    • 주식회사 진켐
    • 우진석송재경김대희강선엽양지영정영수서원민길태건심상희
    • C12N15/54C12N9/10C12N15/09
    • C12N9/1081
    • A novel 2,3-sialyltransferase is provided to mass-produce inexpensively and simply a substance having galatose in its terminal such as 2,3-sialyl lactose which is contained in human milk and inhibits bacterial and viral infection by having strong affinity with influenza A virus hemagglutinin(HA). A novel 2,3-sialyltransferase having the amino acid sequence of SEQ ID NO:1 is isolated from Haemophilus ducreyi(KCTC 2745). A 2,3-sialyltransferase mutant is produced by substituting an amino acid, tyrosine(Tyr) or praline(Pro) at 21 or 112 amino acid position with another amino acid, cysteien(Cys) or glutamine(Gln), respectively. A substance having galatose in its terminal, 2,3-sialyl lactose is produced by reacting a mixture containing CMP(cytidine monophosphate)-N-acetyl neuraminic acid and lactose with 2,3-sialyltransferase or its mutant.
    • 提供了一种新颖的2,3-唾液酸转移酶,可以廉价和简单地大规模生产在其末端具有半乳糖的物质,例如包含在人乳中的2,3-唾液酸乳糖,并通过与流感A具有强亲合力来抑制细菌和病毒感染 病毒血凝素(HA)。 具有SEQ ID NO:1的氨基酸序列的新型2,3-唾液酸转移酶是从嗜血杆菌(KCTC 2745)中分离的。 通过用另一个氨基酸,半胱氨酸(Cys)或谷氨酰胺(Gln)分别在21或112个氨基酸位置取代氨基酸,酪氨酸(Tyr)或脯氨酸(Pro)来产生2,3-唾液酸转移酶突变体。 通过使含有CMP(胞苷苷一磷酸酯)-N-乙酰神经氨酸和乳糖的混合物与2,3-唾液酸转移酶或其突变体反应,得到其末端具有半乳糖的物质2,3-唾液酸乳糖。